摘要
菌落刺激因子(G-CSF) 具有多模型的神经保护作用,并且来自多种转导研究累积的临床数据统计上证实了G-CSF作为一种缺血性中风治疗剂的选择的功效。G-CSF激活了抗凋亡、抗氧化和抗炎的信号通路,并且促进了血管生成和神经再生。本文中,我们总结了在神经保护作用中G-CSF的作用和由G-CSF调节的相应的信号转导通路,并且讨论了其作为一种治疗中风的新药的潜力。
关键词: 菌落刺激因子,神经保护,中风,治疗
Current Medicinal Chemistry
Title:New Missions for an Old Agent: Granulocyte-Colony Stimulating Factor in the Treatment of Stroke Patients
Volume: 22 Issue: 10
Author(s): Ihsan Solaroglu, Murat Digicaylioglu, G. Evren Keles and John H. Zhang
Affiliation:
关键词: 菌落刺激因子,神经保护,中风,治疗
摘要: Granulocyte-colony stimulating factor (G-CSF) has a multimodal neuroprotective profile and the cumulative preclinical data from numerous translational studies statistically confirmed the efficacy of G-CSF as a treatment option in ischemic stroke. G-CSF activates anti-apoptotic, antioxidative, and anti-inflammatory signaling pathways and stimulates angiogenesis and neurogenesis. In this review, we summarize the role of G-CSF and the corresponding signal transduction pathways regulated by G-CSF in neuroprotection and discuss its potential as a new drug for stroke treatment.
Export Options
About this article
Cite this article as:
Ihsan Solaroglu, Murat Digicaylioglu, G. Evren Keles and John H. Zhang , New Missions for an Old Agent: Granulocyte-Colony Stimulating Factor in the Treatment of Stroke Patients, Current Medicinal Chemistry 2015; 22 (10) . https://dx.doi.org/10.2174/0929867322666150209153606
DOI https://dx.doi.org/10.2174/0929867322666150209153606 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Redox Chemistry of Green Tea Polyphenols: Therapeutic Benefits in Neurodegenerative Diseases
Mini-Reviews in Medicinal Chemistry MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry The Glutathione System and its Regulation by Neurohormone Melatonin in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Snake Venom Proteins Isolated from Tunisian Vipers: Pharmacological and Therapeutic Overview
Venoms and Toxins On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia
Current Pharmaceutical Biotechnology Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Current Cardiology Reviews Intracellular Redox State as Target for Anti-Influenza Therapy: Are Antioxidants Always Effective?
Current Topics in Medicinal Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry Renin Angiotensin System and Cytokines in Chronic Kidney Disease: Clinical and Experimental Evidence
Protein & Peptide Letters Endothelial Dysfunction: The Link Between Homocysteine and Hydrogen Sulfide
Current Medicinal Chemistry Antioxidant Activities of Retinoidal Benzimidazole Or Indole Derivatives in In Vitro Model Systems
Current Medicinal Chemistry Functional Components from Nature-Derived Drugs for the Treatment of Rheumatoid Arthritis
Current Drug Targets Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy MiR-106a Associated with Diabetic Peripheral Neuropathy Through the Regulation of 12/15-LOX-meidiated Oxidative/Nitrative Stress
Current Neurovascular Research PF-04886847 (an Inhibitor of Plasma Kallikrein) Attenuates Inflammatory Mediators and Activation of Blood Coagulation in Rat Model of Lipopolysaccharide (LPS) - Induced Sepsis
Cardiovascular & Hematological Agents in Medicinal Chemistry